Barzilai N, Groop P H, Groop L, DeFronzo R A
Division of Endocrinology, Albert Einstein College of Medicine, New York, NY 10461, USA.
Acta Diabetol. 1995 Dec;32(4):273-8. doi: 10.1007/BF00576262.
To examine whether sulfonylureas inhibit the metabolic clearance rate (MCR) of insulin, 19 healthy young subjects participated in two experiments. In the first protocol (n = 10), a 3-h oral glucose load was performed with and without 2 mg of glipizide given 30 min before glucose ingestion. The total insulin response was 60% greater with than without glipizide (5.9 +/- 0.6 vs 3.7 +/- 0.5 microU/ml; P < 0.001). However, the total C-peptide responses were virtually identical (4.7 +/- 0.5 vs 4.8 +/- 0.4 nmol/l) in both studies. In the second protocol (n = 9), the MCR of insulin was measured during 4-h euglycemic insulin clamps performed with and without glipizide. In the study with glipizide, the subjects ingested 5 mg of glipizide at 120 min. The steady-state plasma insulin concentration during the 4th h, i.e., 1-2 h after glipizide ingestion, was significantly higher than during the 2nd h, i.e., before glipizide ingestion (99 +/- 22 vs 78 +/- 17 microU/ml; P < 0.01). In addition, glucose uptake during the 4th h was greater (8.0 +/- 1.6 vs 6.4 +/- 1.5 mg/kg.min) and the MCR of insulin was reduced (503 +/- 126 vs 621 +/- 176 ml/m2.min; P < 0.01). We conclude that glipizide augments plasma insulin levels both by enhancing its secretion and by decreasing the MCR of insulin.
为了研究磺脲类药物是否会抑制胰岛素的代谢清除率(MCR),19名健康的年轻受试者参与了两项实验。在第一个方案(n = 10)中,在摄入葡萄糖前30分钟给予或不给予2毫克格列吡嗪的情况下,进行3小时口服葡萄糖负荷试验。与未使用格列吡嗪相比,使用格列吡嗪时总的胰岛素反应高60%(5.9±0.6对3.7±0.5微单位/毫升;P<0.001)。然而,两项研究中总的C肽反应实际上是相同的(4.7±0.5对4.8±0.4纳摩尔/升)。在第二个方案(n = 9)中,在进行4小时正常血糖胰岛素钳夹试验时,测量使用和不使用格列吡嗪时胰岛素的MCR。在使用格列吡嗪的研究中,受试者在120分钟时摄入5毫克格列吡嗪。第4小时(即摄入格列吡嗪后1 - 2小时)的稳态血浆胰岛素浓度显著高于第2小时(即摄入格列吡嗪前)(99±22对78±17微单位/毫升;P<0.01)。此外,第4小时的葡萄糖摄取量更大(8.0±1.6对6.4±1.5毫克/千克·分钟),胰岛素的MCR降低(503±126对621±176毫升/平方米·分钟;P<0.01)。我们得出结论,格列吡嗪通过增强胰岛素分泌和降低胰岛素的MCR来提高血浆胰岛素水平。